(ERAS) Erasca, Inc. Business Model Canvas Research

Erasca’s drug programs depend on FDA oversight and IRB or IEC review, so these bodies shape dose escalation, safety reporting, and trial go or no-go steps. In FY2025, Erasca was still a clinical-stage company with no product sales, which makes regulator speed and clarity a direct driver of cash burn and trial timing.

• FDA sets dose and safety rules
• IRB or IEC approves each study
• Regulatory feedback changes trial paths

Erasca, Inc. depends on scientific advisers, investors, and licensing partners because oncology drug development is slow and capital heavy; its latest filings show no product revenue, so pipeline progress must be financed externally. These partners help fund long trial timelines, preclinical work, and deal options that can de-risk late-stage programs.

• Funds R&D before sales
• Guides trial design and science
• Shares risk via licensing deals

Erasca, Inc. must keep oral investigational drugs in GMP production, with tight control over sourcing, batch release, packaging, and shipment to trial sites. Reliable supply protects uninterrupted patient dosing, which matters because any delay can pause a study.

• GMP manufacturing for clinical supply
• Controls sourcing to shipment
• Prevents dosing gaps at trial sites

Erasca, Inc. keeps IND maintenance, protocol amendments, and safety reporting moving across its clinical programs, while coordinating trial operations, data review, and regulatory filings. These steps are what push studies through each milestone and keep enrollment, monitoring, and regulator updates aligned.

In practice, this work is the core control layer for clinical development, since every amendment and safety update must stay current for each active study.

• Maintains IND status and filings
• Manages protocol changes and safety reports
• Coordinates trial ops and data review
• Supports progress to clinical milestones

Erasca, Inc. built a key resource in biomarker and pathway know-how around 2 focus areas: RAS/MAPK-driven malignancies and CNS-penetrant EGFR biology. Its read on pathway signaling and resistance helps pick the right patients and set trials apart from broader oncology platforms.

• 2 core biology lanes
• Targets resistance, not just tumors
• Supports sharper patient selection

Erasca, Inc. depends on capital to keep R and D moving across long biopharma timelines, where trials, manufacturing, and FDA work all burn cash before any product revenue arrives. Cash reserves and fresh funding let the Company keep programs alive; when capital tightens, pipeline progress slows fast.

• Funds trials, CMC, and regulatory work
• Supports multi-year pipeline execution
• Prevents delays from cash shortfalls

Erasca, Inc.’s multi-indication pipeline spans 5 oncology settings: non-small cell lung cancer, colorectal cancer, acute myeloid leukemia, advanced solid tumors, and recurrent glioblastoma. That spread lowers single-asset risk and gives Erasca, Inc. multiple shots on goal for clinical and commercial value creation.

• 5 cancer settings
• Lower development concentration risk
• Multiple value-creation shots on goal

ERK1/2 and SHP2 inhibition gives Erasca, Inc. control at both ends of the MAPK pathway: SHP2 cuts upstream signaling, while ERK1/2 blocks the downstream escape route. This matters in tumors that bypass single-node blockade; KRAS mutations drive about 25% of human cancers, and MAPK rewiring is a common resistance driver.

That two-node strategy can widen combination options and may improve reach across tumor types that resist one-target drugs.

• Upstream plus downstream pathway control
• Useful when tumors escape single-node targeting
• Supports combination development
• Fits broader MAPK-driven tumor use

Erasca’s partner management model is highly process driven: the Company coordinates CROs, CMOs, and specialty labs through formal scopes, milestones, and quality checks so outsourced work stays aligned with its drug pipeline. In 2025, Erasca still had no product revenue, so disciplined vendor control remained central to protecting R&D spend and execution speed.

• Coordinates CROs, CMOs, and labs
• Uses structured agreements and milestones
• Keeps outsourced R&D tightly controlled

If Erasca, Inc. reaches commercialization, patient support would need to focus on reimbursement help and treatment education, because oncology care often hinges on prior authorization, copay support, and adherence. In U.S. cancer care, cost and access barriers can delay or disrupt treatment, so the relationship would be built around keeping patients on therapy and reducing drop-off.

• Reimbursement navigation
• Treatment education
• Adherence support

Erasca, Inc. uses earnings releases, 10-Q/10-K filings, and investor decks as its main capital-markets channel, so investors can track pipeline progress, trial milestones, and cash use. This public-company reporting helps shape financing access and keeps shareholders aligned on execution.

• Shows program progress clearly
• Supports capital raising access
• Builds shareholder confidence

If Erasca, Inc. wins approval, its cancer drugs would likely move through oncology specialists and hospital systems, the standard route for complex oncology care. These channels help with prescribing, prior authorization, reimbursement, and patient access, which is critical for high-touch therapies used in advanced cancer settings.

• Oncology specialists drive prescribing.
• Hospital systems support access and reimbursement.

Oncology investigators and cancer centers are Erasca, Inc.'s key operating customers in development: they screen and enroll patients, run study protocols, and generate the evidence regulators and investors need. Their reach matters because only about 3% of U.S. adults with cancer join trials, so site quality and speed directly shape feasibility.

• Enroll patients faster
• Run protocols accurately
• Generate trial evidence
• Drive feasibility and speed

Later-stage biotech assets can draw large pharma because they de-risk late development and can fill pipeline gaps. For Erasca, Inc., this segment can include regional licenses, co-development, or full rights deals that turn clinical progress into upfront cash, milestones, and royalties.

Pharma BD teams still hunt for oncology assets with clear data and strong IP; that’s where future value realization sits for Erasca, Inc..

• Regional rights can widen reach.
• Co-dev shares cost and risk.
• Pipeline adds can lift deal value.

Erasca, Inc. must fund documentation, audits, and pharmacovigilance to keep its oncology pipeline compliant; in regulated drug development, these are non-discretionary costs, not optional overhead. They support safe, lawful testing and post-marketing monitoring, which is why compliance spend rises with each trial stage and regulatory filing.

• Maintains trial records and audit trails
• Runs safety monitoring and reporting systems
• Meets FDA and global GxP rules

In fiscal 2025, Erasca, Inc. kept general and administrative expense material at about $35 million, mainly for finance, legal, HR, and investor relations. That spend supports reporting, governance, and corporate ops, and it stays high even with no product sales.

• Finance and legal are fixed costs.
• IR supports public-market compliance.
• G&A remains meaningful pre-revenue.

If a partner commercializes an Erasca asset, royalties start only after approval and launch, so this is back-end upside with no need for Erasca to sell the drug itself. In Erasca's 2025 filing, it still reported no product revenue, so any future royalty stream would be additive and high-margin.

• Starts after approval and launch
• Partner pays on net sales
• Creates long-tail upside
• No direct commercialization needed
• Current product revenue: zero

Research organizations and public programs can fund selected development work for Erasca, Inc., especially specific studies and translational research. These non-dilutive dollars reduce cash burn, which matters for a biotech that ended 2024 with $340.4 million in cash, cash equivalents, and marketable securities.

• Supports targeted studies
• Covers translational work
• Preserves corporate cash